SEC 13F Intelligence

Managers / Q3 2019 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$150M
Q3 2019
Positions
50
Filings on Record
39
2019–present window
Filed
Nov 12, 2019
original filing

Summary

Birchview Capital, LP reported $150M in U.S.-listed holdings across 50 positions for Q3 2019.

The portfolio is heavily concentrated: CELG alone accounts for 46.3% of reported value.

Compared with Q2 2019, the fund opened 1 new position and exited 5.

Portfolio Metrics

Turnover
+6.5%
vs prior filed quarter
Top-10 Concentration
+87.1%
share of reported value
Largest Position
+46.3%
Celgene
New / Exited
1 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 65.8%Other: 31.8%MLP: 2.2%ADR: 0.2%
  • Common Stock · 65.8% · $99M
  • Other · 31.8% · $48M
  • MLP · 2.2% · $3M
  • ADR · 0.2% · $231,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
KALVISTA PHARMACEUTICALS INCNEW+30.0K30.0K+$348,000$348,000
XBITXBIOTECH INCADDED+20.0K30.0K+$238,000$314,000
EQM MIDSTRM PRTNERS LP LTDADDED+51.3K101.3K+$1M$3M
ARRAY BIOPHARMA INCSOLD OUT−168.0K0−$8M$0
ATARA BIOTHERAPEUTICS INCSOLD OUT−20.0K0−$402,000$0
NEKTAR THERAPEUTICSSOLD OUT−9.5K0−$338,000$0
APELLIS PHARMACEUTICALS INCSOLD OUT−8.0K0−$203,000$0
EQTEQT CORPORATIONSOLD OUT−11.3K0−$179,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CELGCELGENE CORPhistory →COM46.29%$69M699.6K
2ACCELERATE DIAGNOSTICS INCCOM27.02%$41M2.18M
3NBIXNEUROCRINE BIOSCIENCES INChistory →COM3.30%$5M55.0K
4EQM MIDSTRM PRTNERS LP LTDUNIT LTD PARTN2.21%$3M101.3K
5QUIDEL CORPCOM2.00%$3M48.8K
6OXFORD IMMUNOTEC GLOBAL PLCCOM1.89%$3M170.3K
7BMYBRISTOL-MYERS SQUIBB COhistory →COM1.59%$2M47.0K
8VERMILLION INCCOM1.12%$2M3.22M
9DOVADOVA PHARMACEUTICALS INCCOM0.93%$1M50.0K
10MASIMO CORPCOM0.79%$1M8.0K
11BIIBBIOGEN INCCOM0.78%$1M5.0K
12VNDAVANDA PHARMACEUTICALS INCCOM0.71%$1M80.0K
13HROWHARROW HEALTH INCCOM0.67%$1M180.0K
14ARENA PHARMACEUTICALS INCCOM0.67%$1M22.0K
15G1 THERAPEUTICS INCCOM0.61%$911,00040.0K
16AMARIN CORP PLCSPONS ADR NEW0.60%$894,00059.0K
17MYGNMYRIAD GENETICS INCCOM0.57%$859,00030.0K
18DERMIRA INCCOM0.51%$767,000120.0K
19BDQMALBIREO PHARMA INCCOM0.51%$760,00038.0K
20XLRNACCELERON PHARMA INCCOM0.49%$738,00018.7K
21CORTCORCEPT THERAPEUTICS INCCOM0.47%$707,00050.0K
22KARYOPHARM THERAPEUTICS INCCOM0.45%$673,00070.0K
23ARVNARVINAS INCCOM0.43%$647,00030.0K
24WRIGHT MEDICAL GROUP NVCOM0.41%$619,00030.0K
25DICERNA PHARMACEUTICALS INCCOM0.38%$574,00040.0K
26INTERCEPT PHARMACEUTICALS INCCOM0.37%$551,0008.3K
27ODONATE THERAPEUTICS INCCOM0.35%$521,00020.0K
28VYGRVOYAGER THERAPEUTICS INCCOM0.34%$516,00030.0K
29ACADACADIA PHARMACEUTICALS INCCOM0.34%$504,00014.0K
30PIONEER NATURAL RESOURCES COCOM0.32%$478,0003.8K
31IMMUNOGEN INCCOM0.29%$436,000180.0K
32XNCRXENCOR INCCOM0.28%$415,00012.3K
33VCYTVERACYTE INCCOM0.25%$378,00015.8K
34SOLENO THERAPEUTICS INCCOM0.24%$361,000240.6K
35KALVISTA PHARMACEUTICALS INCCOM0.23%$348,00030.0K
36XBITXBIOTECH INCCOM0.21%$314,00030.0K
37AMICUS THERAPEUTICS INCCOM0.20%$305,00038.0K
38SIENTRA INCCOM0.17%$259,00040.0K
39CONTINENTAL RESOURCES INCCOM0.16%$246,0008.0K
40LXRXLEXICON PHARMACEUTICALS INCCOM NEW0.16%$241,00080.0K
41MREOMEREO BIOPHARMA GROUP PLCADS0.15%$231,00077.6K
42ENCANA CORPCOM0.15%$228,00049.5K
43CYTKCYTOKINETICS INCCOM0.08%$114,00010.0K
44WORKHORSE GROUP INCCOM0.06%$88,00025.0K
45TGTXTG THERAPEUTICS INCCOM0.06%$84,00015.0K
46CONTRAFECT CORPCOM0.05%$81,000227.0K
47LIVENT CORPCOM0.04%$67,00010.0K
48YIELD10 BIOSCIENCE INCCOM0.04%$62,000123.6K
49BCRXBIOCRYST PHARMACEUTICALS INCCOM0.04%$57,00020.0K
50AEVI GENOMIC MEDICINE INCCOM0.01%$19,000128.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.